Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21998145 | 0.84 | GPR119 (0.50) | GPR119KDM4EPKM | |
| SCHEMBL22849324 | 0.84 | GPR119 (0.50) | GPR119KDM4EPKM | |
| SCHEMBL29502460 | 0.84 | GPR119 (0.50) | GPR119KDM4EPKM | |
| SCHEMBL25579584 | 0.80 | KCNH2 (0.42) | GPR119KDM4EPKMIDO1KCNH2 | |
| SCHEMBL22848681 | 0.78 | GPR119 (0.52) | GPR119KDM4EPKMIDO1KCNH2 | |
| SCHEMBL22849852 | 0.78 | GPR119 (0.52) | GPR119KDM4EPKMIDO1KCNH2 | |
| SCHEMBL5693198 | 0.77 | L3MBTL1 (0.56) | PKMFFAR1 | |
| SCHEMBL12635860 | 0.74 | KDM4E (0.56) | GPR119KDM4EPKM | |
| SCHEMBL22193191 | 0.74 | ABCB1 (0.52) | KDM4EIDO1KCNH2SCN5ASCN9A | |
| SCHEMBL12697315 | 0.73 | HPGD (0.46) | GPR119KDM4EKCNH2SCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GPR119 2426/4885KDM4E 190/4885PKM 1372/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GPR119 2426/4885KDM4E 190/4885PKM 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.